| | | A double ......
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference
Tuesday April 1, 2014
Sheraton New York Times Square, Friday, April 11, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on PV-10 for cutaneous melanoma will be included in a session at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference. HemOnc Today will be held this year at the Sheraton New York Times Square in New York City on Friday, April 11 and Saturday, April 12.
Dr. Robert H.I. Andtbacka, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, will moderate Session 4: Local and Regional Therapy. Session 4 will be held on Friday, April 11 at 2:15 pm. Sanjiv S. Agarwala, MD, Program Director of the Conference, has said data regarding "PV-10 will be an integral part of session 4." Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study.
Craig Dees, PhD, CEO of Provectus said, "We are very pleased to have our data form such a significant part of this important, cutting-edge conference."
**************
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Tuesday April 1, 2014
PV-10 Selected for Poster Highlights Session
McCormick Place in Chicago, IL, May 30-June 3, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on treatment of cutaneous melanoma using its investigational drug PV-10 have been selected to be part of the Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting this year at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the session are expected to be available on the ASCO website, http://am.asco.org, on April 21, 2014.
Sanjiv S. Agarwala, MD, is lead author of abstract #9027, entitled "Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02."
Craig Dees, PhD, CEO of Provectus said, "Being selected for the Poster Highlights Session is an honor, and we look forward to sharing the results of our Phase 2 study with attendees."
Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study related to cutaneous melanoma and is researching its efficacy for other indications. |
|
